J. Tubprasert

Pharmacometric assessment of the in-vivo antiviral activity of ivermectin in early symptomatic COVID-19

K. Chotivanich, M. Imwong, J. Tarning, 2022, medRxiv.

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants

K. Chotivanich, E. Batty, A. Dondorp, 2022, medRxiv.

In Vitro antimicrobial activity of Zingiber cassumunar (Plai) oil and a 5% Plai oil gel

P. Pithayanukul, J. Tubprasert, M. Wuthi-udomlert, 2007, Phytotherapy research : PTR.

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

C. Cruz, E. Ashley, N. Day, 2020, Wellcome Open Research.

Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings

Debasree Kundu, N. Day, Karthik Gunasekaran, 2021, medRxiv.

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

K. Chotivanich, A. Dondorp, M. Imwong, 2023, eLife.

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

K. Chotivanich, A. Dondorp, M. Imwong, 2023, The Lancet. Infectious diseases.